Immuno-oncology Treatment Devices and Drugs Market Trends

Growth Drivers

• Industry partnerships: The efficiency of products in immuno-oncology treatment devices and drugs market encourages the firms to undertake significant collaborations, contributing to market expansion. For instance, in 2024, Merck announced a partnership with the NHS that resulted in Keytruda expansion to 50,ooo additional patients in the U.S. Besides, Roche acquired a biotech firm to enhance its T-cell engager portfolio, thereby anticipating USD 2.1 billion in added revenue by 2027. Therefore, such collaborations reduce the production costs and facilitate global distribution of the products.

• Heightened technological advancements: There is an accelerated progress in the immuno-oncology treatment devices and drugs market, owing to the innovations in drug delivery and diagnostic procedures. A NIH study in 2024 records that Smart infusion pumps with IoT connectivity resulted in improved patient outcomes by 32%. Besides, the U.S. FDA approved 10 new AI-based diagnostic tools in 2024 for the identification of immunotherapy-responsive tumors. Hence, such milestones reduce treatment delays, projecting a positive market development with optimized dosing.

Challenges

• Expensive treatment procedures: There is a limited reimbursement towards cancer treatment, which hinders patient accessibility in almost all nations. It is noted that the cost associated with CAR-T cell therapies, such as tisagenlecleucel, is approximately $529,200, which in total reaches $511,50 in a span of 90 days post-infusion. Regardless of the presence of reimbursement, it covers only a particular portion of treatment costs, making it challenging for patients to afford it, further deterring growth in the immuno-oncology treatment devices and drugs market.